Amarnath Natarajan

36PUBLICATIONS
91CO-AUTHORS
Molecular targetsBiologically active moleculesMedical devicesCheminformatics and quantitative structure-activity relationshipsMedical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Nov 08, 2026
A Multi-Kinase Inhibitor Screen Identifies mTOR Signaling as a Vulnerability in Advanced Prostate Cancer.

|Oct 29, 2026
Chemical genetic screens combine target dependence with efficacy: discovery of a MAP3K1 degrader (HBC-8) with anticancer activities.

|Sep 26, 2026
Hydrophobic Tag Protein Degraders: An Emerging Therapeutic Strategy for Cancer.

|Apr 13, 2026
MAP3K1: A Multifunctional Kinase at the Crossroads of Cancer Progression and Tumor Suppression.

Lelisse T Umeta, Amarnath Natarajan

|Nov 24, 2025
Surveying the Proteome-Wide Landscape of Mitoxantrone and Examining Drug Sensitivity in BRCA1-Deficient Ovarian Cancer Using Quantitative Proteomics.

Savanna Wallin, Sneha Pandithar, Sarbjit Singh

|May 14, 2025
A Selective MAP3K1 Inhibitor Facilitates Discovery of NPM1 as a Member of the Network.

Lidia Boghean, Sarbjit Singh, Kiran K Mangalaparthi

Pageof 6

Frequent Collaborators

7 joint publications

Sarbjit Singh

6 joint publications

Gloria E O Borgstahl

6 joint publications

Sandeep Rana

5 joint publications

Jayapal Reddy Mallareddy